Incyte's Zynyz, or retifanlimab-dlwr, gained accelerated FDA approval as treatment for adults with recurrent locally advanced or metastatic Merkel cell carcinoma. The approval was based on clinical trial data showing 18% of MCC patients who took the drug achieved a complete response, while 52% achieved a partial or complete response.